Matthew Vesely, MD, PhD

• Ala F Nassar
• Alicia Little
• Amanda Zubek
• Antonella Bacchiocchi
• Brett King
• David Rimm
• Dejian Zhao
• Etienne Caron
• Francesc Lopez-Giraldez
• Francine Foss
• Gilbert Moeckel
• Ian Odell
• Jacky Yeung
• Jeffrey Cohen
• Jennifer McNiff
• Jonathan Leventhal
• Joseph Craft
• Leonard Milstone
• Lieping Chen
• Mario Sznol
• Michael Girardi
• Michal Kidacki
• Murat Gunel
• Peter G. Whang
• Roy S. Herbst
• Ruth Halaban
• Shawn Cowper
• Thazin Nwe Aung
• Weiwei Yu
• William Damsky

Carcinoma, Squamous Cell; Dermatitis; Dermatitis, Atopic; Eczema; Immunoassay; Lichen Planus; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Melanoma; Psoriasis; Skin; Skin and Connective Tissue Diseases; Molecular Imaging

Biomarkers; Clinical Trials; Immunology

• Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor OutcomesVesely M, Kidacki M, Gaule P, Gupta S, Chan N, Han X, Yeung J, Chen L. Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes. Journal Of Investigative Dermatology 2023, 144: 106-115.e4. PMID: 37562584, DOI: 10.1016/j.jid.2023.07.008.
• Resistance Mechanisms to Anti-PD Cancer ImmunotherapyVesely MD, Zhang T, Chen L. Resistance Mechanisms to Anti-PD Cancer Immunotherapy. Annual Review Of Immunology 2022, 40: 45-74. PMID: 35471840, DOI: 10.1146/annurev-immunol-070621-030155.
• The CD8α–PILRα interaction maintains CD8+ T cell quiescenceZheng L, Han X, Yao S, Zhu Y, Klement J, Wu S, Ji L, Zhu G, Cheng X, Tobiasova Z, Yu W, Huang B, Vesely MD, Wang J, Zhang J, Quinlan E, Chen L. The CD8α–PILRα interaction maintains CD8+ T cell quiescence. Science 2022, 376: 996-1001. PMID: 35617401, DOI: 10.1126/science.aaz8658.
• T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanomaLozano AX, Chaudhuri AA, Nene A, Bacchiocchi A, Earland N, Vesely MD, Usmani A, Turner BE, Steen CB, Luca BA, Badri T, Gulati GS, Vahid MR, Khameneh F, Harris PK, Chen DY, Dhodapkar K, Sznol M, Halaban R, Newman AM. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nature Medicine 2022, 28: 353-362. PMID: 35027754, PMCID: PMC8866214, DOI: 10.1038/s41591-021-01623-z.
• PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosusHan X, Vesely MD, Yang W, Sanmamed MF, Badri T, Alawa J, López-Giráldez F, Gaule P, Lee SW, Zhang JP, Nie X, Nassar A, Boto A, Flies DB, Zheng L, Kim TK, Moeckel GW, McNiff JM, Chen L. PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus. Science Translational Medicine 2019, 11 PMID: 31826980, DOI: 10.1126/scitranslmed.aax1159.
• Cutaneous Lupus Erythematosus: Current and Future Pathogenesis-Directed Therapies.Little AJ, Vesely MD. Cutaneous Lupus Erythematosus: Current and Future Pathogenesis-Directed Therapies. The Yale Journal Of Biology And Medicine 2020, 93: 81-95. PMID: 32226339, PMCID: PMC7087060.
• Cancer Immunoediting in the Era of Immuno-oncology.Gubin MM, Vesely MD. Cancer Immunoediting in the Era of Immuno-oncology. Clinical Cancer Research 2022, 28: 3917-3928. PMID: 35594163, PMCID: PMC9481657, DOI: 10.1158/1078-0432.ccr-21-1804.
• Not all well-differentiated cutaneous squamous cell carcinomas are equal: Tumors with disparate biologic behavior have differences in protein expression via digital spatial profilingVesely M, Martinez-Morilla S, Gehlhausen JR, McNiff JM, Whang PG, Rimm D, Ko CJ. Not all well-differentiated cutaneous squamous cell carcinomas are equal: Tumors with disparate biologic behavior have differences in protein expression via digital spatial profiling. Journal Of The American Academy Of Dermatology 2022, 87: 695-698. PMID: 35398219, DOI: 10.1016/j.jaad.2022.03.057.
• Pembrolizumab-induced lichenoid dermatitis treated with dupilumabPark J, Park E, Damsky W, Vesely M. Pembrolizumab-induced lichenoid dermatitis treated with dupilumab. JAAD Case Reports 2023, 37: 13-15. PMID: 37332364, PMCID: PMC10275729, DOI: 10.1016/j.jdcr.2023.05.004.
• Treatment of cutaneous lupus with topical ruxolitinib creamPark JJ, Little AJ, Vesely MD. Treatment of cutaneous lupus with topical ruxolitinib cream. JAAD Case Reports 2022, 28: 133-135. PMID: 36159722, PMCID: PMC9494033, DOI: 10.1016/j.jdcr.2022.08.038.
• HIF-1 regulates pathogenic cytotoxic T cells in lupus skin diseaseLittle A, Chen P, Vesely M, Khan R, Fiedler J, Garritano J, Islam F, McNiff J, Craft J. HIF-1 regulates pathogenic cytotoxic T cells in lupus skin disease. JCI Insight 2023, 8: e166076. PMID: 37526979, PMCID: PMC10543720, DOI: 10.1172/jci.insight.166076.
• Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlightsNoelle R, Lines J, Lewis L, Martell R, Guillaudeux T, Lee S, Mahoney K, Vesely M, Boyd-Kirkup J, Nambiar D, Scott A. Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights. Frontiers In Oncology 2023, 13: 1225081. PMID: 37795437, PMCID: PMC10547146, DOI: 10.3389/fonc.2023.1225081.
• Crusted Scabies Presenting as Erythroderma in a Patient With Iatrogenic Immunosuppression for Treatment of Granulomatosis With Polyangiitis.Olamiju B, Leventhal J, Vesely M. Crusted Scabies Presenting as Erythroderma in a Patient With Iatrogenic Immunosuppression for Treatment of Granulomatosis With Polyangiitis. Cutis 2023, 111: e44-e47. PMID: 37406327, DOI: 10.12788/cutis.0794.
• Amelanotic melanoma in a patient with Hermansky-Pudlak syndromeFan R, Johnston MS, Gowen MF, Damsky W, Odell I, Clune J, Vesely MD. Amelanotic melanoma in a patient with Hermansky-Pudlak syndrome. JAAD Case Reports 2022, 27: 61-63. PMID: 35990226, PMCID: PMC9388864, DOI: 10.1016/j.jdcr.2022.06.035.
• Fever, Hypotension, and a Worsening Necrotic WoundPeterson DM, Damsky WE, Vesely MD. Fever, Hypotension, and a Worsening Necrotic Wound. JAMA 2022, 327: 1496-1497. PMID: 35311923, DOI: 10.1001/jama.2022.2806.
• Treatment of lichen sclerosus and hypertrophic scars with dupilumabPeterson DM, Damsky WE, Vesely MD. Treatment of lichen sclerosus and hypertrophic scars with dupilumab. JAAD Case Reports 2022, 23: 76-78. PMID: 35445148, PMCID: PMC9014314, DOI: 10.1016/j.jdcr.2022.03.002.
• A pruritic psoriatic plaque develops at the donor site of an autologous skin graft: Koebner phenomenonMurphy MJ, Damsky W, Vesely MD. A pruritic psoriatic plaque develops at the donor site of an autologous skin graft: Koebner phenomenon. The Lancet 2021, 398: 1836. PMID: 34774145, DOI: 10.1016/s0140-6736(21)02332-1.
• Cytokine RNA In Situ Hybridization Permits Individualized Molecular Phenotyping in Biopsies of Psoriasis and Atopic DermatitisWang A, Fogel AL, Murphy MJ, Panse G, McGeary MK, McNiff JM, Bosenberg M, Vesely MD, Cohen JM, Ko CJ, King BA, Damsky W. Cytokine RNA In Situ Hybridization Permits Individualized Molecular Phenotyping in Biopsies of Psoriasis and Atopic Dermatitis. JID Innovations 2021, 1: 100021. PMID: 34909719, PMCID: PMC8659380, DOI: 10.1016/j.xjidi.2021.100021.
• Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomasYeung J, Yaghoobi V, Miyagishima D, Vesely MD, Zhang T, Badri T, Nassar A, Han X, Sanmamed MF, Youngblood M, Peyre M, Kalamarides M, Rimm DL, Gunel M, Chen L. Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. Neuro-Oncology 2021, 23: 1922-1935. PMID: 33914067, PMCID: PMC8563319, DOI: 10.1093/neuonc/noab075.
• Necrotic papulonodules on the legsZhou A, Damsky W, Girardi M, Foss FM, Vesely MD. Necrotic papulonodules on the legs. JAAD Case Reports 2021, 11: 10-12. PMID: 33898676, PMCID: PMC8056172, DOI: 10.1016/j.jdcr.2021.03.012.
• A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer ImmunotherapySanmamed MF, Nie X, Desai SS, Villaroel-Espindola F, Badri T, Zhao D, Kim AW, Ji L, Zhang T, Quinlan E, Cheng X, Han X, Vesely MD, Nassar AF, Sun J, Zhang Y, Kim TK, Wang J, Melero I, Herbst RS, Schalper KA, Chen L. A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy. Cancer Discovery 2021, 11: 1700-1715. PMID: 33658301, PMCID: PMC9421941, DOI: 10.1158/2159-8290.cd-20-0962.
• Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapyPeterson DM, Vesely MD. Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapy. JAAD Case Reports 2021, 10: 4-7. PMID: 33728367, PMCID: PMC7935686, DOI: 10.1016/j.jdcr.2021.01.020.
• Spatially Resolved and Quantitative Analysis of the Immunological Landscape in Human MeningiomasYeung J, Yaghoobi V, Aung TN, Vesely MD, Zhang T, Gaule P, Gunel M, Rimm DL, Chen L. Spatially Resolved and Quantitative Analysis of the Immunological Landscape in Human Meningiomas. Journal Of Neuropathology & Experimental Neurology 2021, 80: 150-159. PMID: 33393633, DOI: 10.1093/jnen/nlaa152.
• Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysisMurphy MJ, Cohen JM, Vesely MD, Damsky W. Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis. Journal Of The American Academy Of Dermatology 2020, 86: 1080-1091. PMID: 33307146, DOI: 10.1016/j.jaad.2020.12.010.
• Onychodystrophy associated with dupilumab therapy for atopic dermatitisZubek AE, Vesely MD. Onychodystrophy associated with dupilumab therapy for atopic dermatitis. JAAD Case Reports 2020, 7: 20-22. PMID: 33318995, PMCID: PMC7727284, DOI: 10.1016/j.jdcr.2020.10.024.
• Caution in the time of rashes and COVID-19Vesely MD, Perkins SH. Caution in the time of rashes and COVID-19. Journal Of The American Academy Of Dermatology 2020, 83: e321-e322. PMID: 32682026, PMCID: PMC7362801, DOI: 10.1016/j.jaad.2020.07.026.
• A rapidly growing, exophytic nodule on the chestRamseier JY, Cowper SE, Leventhal JS, Vesely MD. A rapidly growing, exophytic nodule on the chest. JAAD Case Reports 2020, 6: 417-419. PMID: 32382633, PMCID: PMC7200183, DOI: 10.1016/j.jdcr.2020.02.038.
• In silico analysis of the immunological landscape of pituitary adenomasYeung JT, Vesely MD, Miyagishima DF. In silico analysis of the immunological landscape of pituitary adenomas. Journal Of Neuro-Oncology 2020, 147: 595-598. PMID: 32236778, PMCID: PMC7261241, DOI: 10.1007/s11060-020-03476-x.
• Getting Under the Skin: Targeting Cutaneous Autoimmune Disease.Vesely MD. Getting Under the Skin: Targeting Cutaneous Autoimmune Disease. The Yale Journal Of Biology And Medicine 2020, 93: 197-206. PMID: 32226348, PMCID: PMC7087062.
• Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patientPeterson DM, Vesely MD. Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient. JAAD Case Reports 2020, 6: 257-259. PMID: 32258291, PMCID: PMC7109366, DOI: 10.1016/j.jdcr.2020.02.007.
• Tense Bullae and Pruritus.Vesely MD, Olamiju BA, Leventhal JS. Tense Bullae and Pruritus. American Family Physician 2020, 101: 305-306. PMID: 32109022, PMCID: PMC7255498.
• Normalization Cancer Immunotherapy for MelanomaVesely MD, Chen L. Normalization Cancer Immunotherapy for Melanoma. Journal Of Investigative Dermatology 2020, 140: 1134-1142. PMID: 32092349, PMCID: PMC7247948, DOI: 10.1016/j.jid.2020.02.005.
• Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinibDamsky WE, Vesely MD, Lee AI, Choi J, Meyer AC, Chen M, Ahmad T, King B. Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib. JAAD Case Reports 2019, 5: 1018-1026. PMID: 31763425, PMCID: PMC6864390, DOI: 10.1016/j.jdcr.2019.07.004.
• Genetic Autoinflammatory DisordersPediatric Dermatology and Dermatopathology
• Chapter One Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal AntibodiesHan X, Vesely MD. Chapter One Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies. 2018, 342: 1-25. PMID: 30635089, PMCID: PMC6487201, DOI: 10.1016/bs.ircmb.2018.07.003.
• Tofacitinib citrate for the treatment of refractory, severe chronic actinic dermatitisVesely MD, Imaeda S, King BA. Tofacitinib citrate for the treatment of refractory, severe chronic actinic dermatitis. JAAD Case Reports 2016, 3: 4-6. PMID: 28050588, PMCID: PMC5192094, DOI: 10.1016/j.jdcr.2016.09.008.
• A Serendipitous Retreat into Research Techniques Made SimpleVesely MD. A Serendipitous Retreat into Research Techniques Made Simple. Journal Of Investigative Dermatology 2016, 136: e123. PMID: 27884294, PMCID: PMC7232641, DOI: 10.1016/j.jid.2016.10.009.
• Recurrent Coxsackievirus Infection in a Patient with Lamellar IchthyosisDamsky WE, Leventhal JS, Khalil D, Vesely MD, Craiglow BG, Milstone LM, Choate KA. Recurrent Coxsackievirus Infection in a Patient with Lamellar Ichthyosis. Pediatric Dermatology 2016, 33: e140-e142. PMID: 26821985, PMCID: PMC7226923, DOI: 10.1111/pde.12769.
• Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigensGubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515: 577-581. PMID: 25428507, PMCID: PMC4279952, DOI: 10.1038/nature13988.
• Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapyVesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Annals Of The New York Academy Of Sciences 2013, 1284: 1-5. PMID: 23651186, PMCID: PMC3648872, DOI: 10.1111/nyas.12105.
• Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium StateTeng MW, Vesely MD, Duret H, McLaughlin N, Towne JE, Schreiber RD, Smyth MJ. Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State. Cancer Research 2012, 72: 3987-3996. PMID: 22869585, PMCID: PMC4384890, DOI: 10.1158/0008-5472.can-12-1337.
• Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoeditingMatsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482: 400-404. PMID: 22318521, PMCID: PMC3874809, DOI: 10.1038/nature10755.
• Natural Innate and Adaptive Immunity to CancerVesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural Innate and Adaptive Immunity to Cancer. Annual Review Of Immunology 2011, 29: 235-271. PMID: 21219185, DOI: 10.1146/annurev-immunol-031210-101324.
• Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesisSwann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, Smyth MJ. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2008, 105: 652-656. PMID: 18178624, PMCID: PMC2206591, DOI: 10.1073/pnas.0708594105.
• Evidence for an Atrial Natriuretic Peptide–-Like Gene in PlantsVesely M, Gower W, Perez-Lamboy G, Overton R, Graddy L, Vesely D. Evidence for an Atrial Natriuretic Peptide–-Like Gene in Plants. Experimental Biology And Medicine 2001, 226: 61-65. PMID: 11368240, DOI: 10.1177/153537020122600109.
• Environmental Upregulation of the Atrial Natriuretic Peptide Gene in the Living Fossil,Limulus polyphemusVesely M, Vesely D. Environmental Upregulation of the Atrial Natriuretic Peptide Gene in the Living Fossil,Limulus polyphemus. Biochemical And Biophysical Research Communications 1999, 254: 751-756. PMID: 9920813, DOI: 10.1006/bbrc.1998.9990.